Skip to main content
. Author manuscript; available in PMC: 2017 Aug 8.
Published in final edited form as: Curr Biol. 2016 Jul 14;26(15):2037–2043. doi: 10.1016/j.cub.2016.06.002

Figure 2. ATF5 is required for UPRmt activation in mammalian cells.

Figure 2

(A) Expression levels of HSP60, mtHSP70, LONP1, and HD-5 mRNA in control or ATF5 shRNA HEK 293T cells with or without paraquat (PQ) (n=3, mean ± SEM, *p<0.05).

(B) Schematic showing ΔOTC construct. Photomicrographs of hsp-60pr::gfp worms raised on control or atfs-1(RNAi) with or without ΔOTC expression via the muscle-specific myo-3 promoter. Scale bar, 0.5 mm.

(C) Expression levels of HSP60, mtHSP70, and LONP1 mRNA in control or ATF5 shRNA HEK 293T cells with or without ΔOTC expression (n=3, mean ± SEM, *p<0.05)

(D) Expression levels of ATF5 mRNA in control or ATF5 shRNA HEK 293T cells with or without paraquat (PQ), or expressing ΔOTC (n=3, mean ± SEM, *p<0.05).

(E) Expression levels of LONP1 mRNA in control or ATF5 shRNA HEK 293T cells treated with oligomycin, antimycin, piericidin, or all three inhibitors (n=3, mean ± SEM, *p<0.05). See also Figure S2.